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Voiding Dysfunction
α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase 
Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 
10 Years’ Long-Term Results
Teak Jun Shin, Chun Il Kim, Choal Hee Park, Byung Hoon Kim, Young Kee Kwon
Department of Urology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
Purpose: We compared the effects of alpha-adrenergic receptor blocker (α-blocker) mon-
otherapy with those of combination therapy with α-blocker and 5-alpha-reductase in-
hibitor (5-ARI) on benign prostatic hyperplasia (BPH) progression for over 10 years.
Materials and Methods: A total of 620 patients with BPH who received α-blocker mono-
therapy (α-blocker group, n=368) or combination therapy (combination group, n=252) 
as their initial treatment were enrolled from January 1989 to June 2000. The incidences 
of acute urinary retention (AUR) and BPH-related surgery were compared between the 
two groups. Incidences stratified by follow-up period, prostate-specific antigen (PSA), 
and prostate volume (PV) were compared between the two groups.
Results: The incidence of AUR was 13.6% (50/368) in the α-blocker group and 2.8% 
(7/252) in the combination group (p＜0.001). A total of 8.4% (31/368) and 3.2% (8/252) 
of patients underwent BPH-related surgery in the α-blocker and combination groups, 
respectively (p=0.008). According to the follow-up period, the incidence of AUR was sig-
nificantly decreased in combination group. However, the incidence of BPH-related sur-
gery was significantly reduced after 7 years of combination therapy. Cutoff levels of 
PSA and PV for reducing the incidences of AUR and BPH-related surgery were 2.0 ng/ml 
and 35 g, respectively (p＜0.001).
Conclusions: Long-term combination therapy with α-blocker and 5-ARI can suppress 
the progression of BPH more efficiently than α-blocker monotherapy. For patients with 
BPH with PSA ＞2.0 ng/ml or PV ＞35 ml, combination therapy promises a better effect 
for reducing the risk of BPH progression. 
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is a progressive dis-
ease that can cause acute urinary retention (AUR) and that 
leads to BPH-related surgery [1-3]. At present, alpha-adre-
nergic receptor blockers (α-blockers) and 5-alpha-reduc-
tase inhibitors (5-ARIs) are used in the medical therapy of 
BPH. Most doctors in the 1990s, however, preferred α-bloc-
ker monotherapy to the combination therapy of α-blockers 
and 5-ARIs. This preference was based on the results of 
many studies, including a Veterans Affairs Cooperative 
study and a Prospective European Doxazosin and Combi-
nation Therapy Trial study, that reported no significant 
difference in short-term effects on the treatment of BPH be-
tween α-blocker monotherapy and the combination ther-
apy with an α-blocker and 5-ARI [4,5]. In contrast to these 
reports, the Medical Therapy of Prostatic Symptoms 
(MTOPS) study reported that during 4.5 years of follow-up, 
the progression of BPH, the worsening of symptoms, and 
BPH-related surgeries decreased more in the doxazosin Korean J Urol 2012;53:248-252
α-Blocker Monotherapy vs. 5-ARI Combination Treatment  249
TABLE 1. Incidence of AUR and BPH-related surgery in the α-blocker monotherapy and combination treatment groups
Event Parameter
No. of patients (%)
p-value α-blocker group
n=358
Combination group
n=252
AUR
BPH-related surgery
All
PSA≤2.0 ng/ml
PSA＞2.0 ng/ml
PV≤35 ml
PV＞35 ml
All
PSA≤2.0 ng/ml
PSA＞2.0 ng/ml
PV≤35 ml
PV＞35 ml
50 (13.6)
13 (6.0)
37 (24.2)
12 (5.3)
38 (27.0)
31 (8.4)
5 (2.3)
26 (17.0)
2 (0.9)
29 (20.6)
7 (2.8)
2 (1.7)
5 (3.8)
1 (1.0)
6 (4.0)
8 (3.2)
3 (2.6)
5 (3.8)
1 (1.0)
7 (4.7)
＜0.001
0.065
＜0.001
0.064
＜0.001
0.008
0.902
＜0.001
0.921
＜0.001
AUR, acute urinary retention; BPH, benign prostatic hyperplasia; PSA, prostate-specific antigen; PV, prostate volume. 
and finasteride combination group than in the doxazosin 
or finasteride monotherapy group [6]. Furthermore, Kim 
et al. [7] reported that the incidences of AUR and BPH-re-
lated surgeries in a combination therapy group were sig-
nificantly decreased for 6 to 8 years.
In the present study, the authors analyzed the long-term 
effects of α-blocker monotherapy and combination therapy 
with an α-blocker and 5-ARI in actual clinical studies for 
over 10 years and examined the incidences of AUR and 
BPH-related surgeries by prostate volume (PV) and pros-
tate-specific antigen (PSA) level. 
MATERIALS AND METHODS
This study investigated the medical records of 620 BPH pa-
tients who received medical therapy for at least 1 year be-
tween January 1989 and July 2010, retrospectively. This 
study excluded patients who were under 40 years of age; 
those with an International Prostate Symptom Score 
(IPSS) of 7 or lower; those whose maximal urinary flow rate 
(Qmax) was 15 ml/s or higher; patients who had received 
medical treatment for BPH previously; patients who had 
received combination medication with anticholinergics; 
patients who had undergone BPH-related surgery, urinary 
bladder surgery, urethroplasty, or diathermy; and pa-
tients who had lower urinary tract symptoms (LUTS) due 
to causes other than BPH. Also excluded were patients who 
had AUR or who had undergone a BPH-related surgery 
within 12 months after beginning medical treatment and 
patients who were confirmed to have prostate cancer and 
BPH simultaneously.
The follow-up period of this study was determined by the 
AUR onset date, BPH-related surgery date, or last visit 
date in the medical records. For subjects who were not fol-
lowed up, information on the continuation of medical treat-
ment, AUR, or BPH-related surgery was collected via mail 
or phone surveys. 
The patients were divided into the α-blocker group, who 
received  α-blocker monotherapy, and the combination 
group, who received combination therapy of α-blocker and 
5-ARI. The incidences of AUR and BPH-related surgeries 
were compared between these two groups and also between 
patients who were classified by PV and serum PSA level. 
To calculate PV, transrectal ultrasonography was per-
formed. The anteroposterior (H) and transverse (W) leng-
ths were measured from the longest transverse image of 
the prostate. The horizontal length from the proximal to 
the distal parts of the prostate in the midline sagittal scan 
was regarded as the longitudinal (L) length. To calculate 
PV, the following equation was used: PV=π/6x HxWxL.
To stratify PSA levels and PV, their relationships with 
AUR and BPH-related surgeries were examined by using 
receiver operating characteristic (ROC) curves. 
RESULTS
Of the 620 patients, 368 belonged to the α-blocker group 
and 252 to the combination group. In the α-blocker and 
combination groups, respectively, the mean age was 64.2 
years (range, 29 to 91 years) and 64.8 years (range, 40 to 
89 years) (p=0.470), and the average follow-up period was 
108.6 months (range, 12 to 216 months) and 113.1 months 
(range, 12 to 170 months) (p=0.206). The PSA levels at the 
first visit of the α-blocker group and the combination group 
were 2.2 ng/ml and 2.9 ng/ml (p=0.082), respectively, and 
the PVs were 37.5 ml and 42.9 ml (p=0.064), respectively.
AUR developed in 9.2% (57/620) of the total group: 13.6% 
(50/368) in the α-blocker group and 2.8% (7/252) in the com-
bination group. Thus, the hazard ratio of the combination 
group was lower by 79.4% than that of the α-blocker group 
(p＜0.001) (Table 1, Fig. 1). The incidence of BPH-related 
surgeries was 8.4% (31/368) for the α-blocker group and 
3.2% (8/252) for the combination group. Thus, the hazard 
ratio of the combination group was 61.9% lower than that 
of the α-blocker group (p=0.008) (Fig. 2). 
The incidence of BPH-related surgery was 5.4% for the 
α-blocker group and 2.4% for the combination group for up 
to 7 years of follow-up and the difference was not signifi-Korean J Urol 2012;53:248-252
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FIG. 1. Cumulative incidences of acute urinary retention (AUR) 
in the α-blocker monotherapy and combination treatment 
groups. 
FIG. 2. Cumulative incidences of benign prostatic hyperplasia 
(BPH) related surgery in the α-blocker monotherapy and 
combination treatment groups.
cant. For longer periods of follow-up, however, the in-
cidence of BPH-related surgery was significantly lower in 
the combination group. The incidence of AUR was sig-
nificantly lower in the combination group for follow-up pe-
riods of 2 years or longer.
The cutoff level of PSA and PV for the hazards of AUR 
and BPH-related surgery were 2.0 ng/ml and 35 ml, 
respectively. When the PSA level was higher than 2.0 
ng/ml, the incidence of AUR in the α-blocker and combina-
tion groups was 24.2% (37/153) and 3.8% (5/133), respec-
tively; when the PV was higher than 35 ml, the incidence 
of AUR was 27.0% (38/141) and 4.0% (6/150), respectively 
(p＜0.001). When the PSA level was higher than 2.0 ng/ml, 
the incidence of BPH-related surgery in the α-blocker and 
combination groups was 17.0% (26/153) and 3.8% (5/133), 
respectively; when the PV was higher than 35 ml, the in-
cidence of BPH-related surgery was 20.6% (29/141) and 
4.7% (7/150), respectively (p＜0.001).
Of the 39 patients who underwent BPH-related sur-
geries, 10 received surgeries due to AUR, and the other 29 
received surgeries due to insufficient efficacy of drug 
treatment. 
DISCUSSION
BPH can cause various complications, such as AUR, 
BPH-related surgeries, urinary incontinence, and urinary 
tract infection [8]. Between α-blockers and 5-ARIs, which 
are the representative drug treatments for BPH, 5-ARIs 
are being spotlighted in that they can prevent BPH 
progression. In the past, however, most studies were skep-
tical about the effects of combination therapy with α-block-
ers and 5-ARIs. The Veterans Affairs Cooperative Study 
showed that α-blocker monotherapy and 5-ARI combina-
tion therapy for 12 months decreased the American Urolo-
gical Association symptom score to 6.1 and 6.2, and in-
creased Qmax to 2.7 and 3.2, with no significant differences 
between the two therapies [4]. The Prospective European 
Doxazosin and Combination Therapy Trial reported that 
α-blocker monotherapy and 5-ARI combination therapy in-
creased Qmax to 3.6 and 3.8 ml/s, and decreased IPSS to 
8.3 and 8.5, with no significant differences between the two 
therapies [5]. These studies, however, compared the effects 
of drug treatment for short periods of 1 year or less and fo-
cused on comparing the changes in LUTS and Qmax rather 
than on the complications of BPH.
The effects of 5-ARIs were described better in the Proscar 
Long-Term Efficacy and Safety Study [2]. This study used 
finasteride for 4 years, which decreased PV by 18% com-
pared with the placebo group and decreased the incidences 
of AUR and BPH-related surgeries to 57% and 55%, 
respectively. Later, the MTOPS study also reported the ef-
fects of treatments with α-blocker and 5-ARI for 4.5 years 
[6]. Compared with that in the doxazosin group, the AUR 
hazard of the combination group decreased by 75%, and the 
hazard of BPH-related surgeries decreased by 64% and 
67% in the finasteride monotherapy group and the combi-
nation therapy group, respectively. The PV increased by 
24% in the placebo group and the doxazosin group but de-
creased by 13% and 16% in the finasteride group and the 
combination group, respectively. 
AUR is not only a serious complication of BPH, but also 
an important indication for BPH-related surgery. Among 
the many causes of AUR, BPH accounts for 50% [9]. The 
PSA level in the serum has shown a close correlation with 
PV [10]. Roehrborn et al. [11] reported that the risk of AUR 
in patients whose PSA level was 3.4 ng/ml or higher was 
4 times that of patients whose PSA level was 1.2 ng/ml or Korean J Urol 2012;53:248-252
α-Blocker Monotherapy vs. 5-ARI Combination Treatment  251
lower. Furthermore, they reported that the risk of AUR in 
the patients whose PV was 57 g or higher was 3.5 times that 
of the patients whose PV was 34 g or lower. Jacobsen et al. 
[12] also reported that when PV exceeded 30 g, the AUR in-
cidence increased at least 3 times. The European Associa-
tion of Urology Guidelines strongly recommended drug 
treatment with finasteride for patients who have BPH and 
serious LUTS and whose PV is greater than 40 g. Bartch 
et al. [13] suggested that the treatment with 5-ARI would 
prevent the progress of potential BPH for patients whose 
serum PSA level is 1.5 ng/ml or higher or whose PV is 30 
g or greater. To determine the effect of the treatment meth-
od, Kaplan et al. [14] divided patients into three groups (PV 
smaller than 25 g, 25 to 40 g, or greater than 40 g) for the 
results of the MTOPS study. The hazard of BPH pro-
gression of the group whose PV was smaller than 25 g did 
not significantly change between the combination group 
and the doxazosin or finasteride group; however, in the 
group whose PV was greater than 25 g, the hazard of BPH 
progression of the combination group decreased compared 
with that of the doxazosin or finasteride group. Further-
more, the incidence of invasive surgeries in the combina-
tion group decreased by 70% compared with the doxazosin 
group.
A recent CombAT study set the cutoff level for patients 
with a high hazard of disease progression as a serum PSA 
value of 1.5 g/l or higher and a PV of 30 ml or greater [15]. 
A 4-year study with these patients found that the incidence 
of BPH progression (IPSS score 4 or higher, AUR, incon-
tinence, relapsing urinary tract infection, or renal in-
adequacy) was 12.6% in the combination group treated 
with dutasteride and tamsulosin, 17.8% in the dutasteride 
group, and 21.5% in the tamsulosin group. In the combina-
tion group, the decrease in the hazard associated with pros-
tate progression was statistically significant. Compared 
with that in the tamsulosin group, the AUR hazard, 
BPH-related surgeries, and IPSS score of the combination 
group decreased by 67.8%, 70.6%, and 41.3%, respectively 
[16]. 
The study by Lee et al. [17] that was conducted at 5 medi-
cal centers in Korea compared an α-blocker monotherapy 
group and a combination therapy group according to PV, 
PSA, IPSS, and Qmax. During the 4-year follow-up, the 
IPSS score of the monotherapy group decreased by 6.1, but 
that of the combination group decreased by 11.5, which was 
an improved result. 
The present study compared an α-blocker group with a 
combination group: the AUR incidence was 13.6% and 
2.8%, respectively, and the incidence of BPH-related sur-
geries was 8.4% and 3.2%, respectively. The authors did not 
find significant differences in the length of AUR incidence 
between the two groups of patients whose PV was 35 g or 
lower and serum PSA level was 2.0 ng/ml or lower. Compa-
red with that in the α-blocker group, the AUR incidence in 
the combination group decreased by 85.2% and 84.3% in pa-
tients whose PV exceeded 35 g and whose serum PSA level 
exceeded 2.0 ng/ml, respectively, and the incidence of 
BPH-related surgeries decreased by 77.2% and 77.6%, 
respectively.
The present study was meaningful because it was a 
long-term study of 10 years of actual clinical data rather 
than a prospective random contrast study. The incidences 
of AUR and BPH-related surgeries in the BPH patients 
who received combination therapy with 5-ARI were sig-
nificantly lower than those in the patients who received 
α-blocker monotherapy. These results are similar to those 
of previous studies and show that combination therapy 
with 5-ARI is helpful even with long-term treatment of 10 
years.
The data of our study, including PSA change, prostate 
size change, IPSS change, residual urine change, and flow 
rate change, are not enough because the study was retro-
spective. Thus, our study has limitations concerning abso-
lute assessment. Therefore, more extensive research is be-
lieved to be necessary in the future. 
CONCLUSIONS
With the use of actual clinical data, the present study found 
that the combination group that used an α-blocker and a 
5-ARI for a long period of 10 years had a decreased hazard 
of BPH progression, such as AUR and BPH-related sur-
geries, compared with the α-blocker monotherapy group. 
Furthermore, in patients whose PV and serum PSA level 
exceeded 35 g and 2.0 ng/ml, respectively, combination 
therapy was more effective than monotherapy in decreas-
ing the incidences of AUR and BPH-related surgeries. 
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